Newsletter
292 – Improving clinical trials with AI. Michelle Gallaher, Opyl

Talking HealthTech

292 – Improving clinical trials with AI. Michelle Gallaher, Opyl

Disruption is not a dirty word: improving clinical trials with AI   Michelle Gallaher is a reasonably well-known contributor to the Australian biotech, MedTech, and digital health sector. She leads…
September 29, 2022

292 – Improving clinical trials with AI. Michelle Gallaher, Opyl

Disruption is not a dirty word: improving clinical trials with AI

 

Michelle Gallaher is a reasonably well-known contributor to the Australian biotech, MedTech, and digital health sector. She leads a small cap listed company, Opyl in the application of AI to improve clinical trials.

Opyl is a new generation company that applies artificial intelligence in clinical trials and social media to improve healthcare.

 

In this episode, learn how AI may be used to enhance clinical trials.

Have you ever wondered how clinical trials have changed over time? This episode will show you how artificial intelligence is used in clinical trials, specifically in participant recruitment and protocol design.

 

Check out the episode and full show notes here.

Loving the show?  Leave us a review, and share it with someone who might get some value from it.

Keen to take your healthtech to the next level? Become a THT+ Member for access to our online community forum, quarterly summits and more exclusive content.  For more information visit here.

You may also like

Subscribe to Health Podcast Network

Join Our Newsletter

Proudly supported by:

cover
What are the Early Stages of Alzheimer’s Disease? Despite significant breakthroughs in medical knowledge, Alzheimer’s disease is still shrouded in stigma and misconception. In this episode, we hear personal stories of what living with Alzheimer’s is like.